Las Vegas, NV -- (SBWIRE) -- 01/15/2014 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: North American Palladium Ltd (USA) (NYSEMKT:PAL), New Gold Inc. (USA) (NYSEMKT:NGD), Cell Therapeutics Inc (NASDAQ:CTIC), China Pharma Holdings, Inc. (NYSEMKT:CPHI).
North American Palladium Ltd (USA) (NYSEMKT:PAL) ended its recent business day with the tumbled of -11.58% and closed at the price of $0.610 after opening at $0.65. The stock traded during its last trading session with the total volume of 4.68 million shares, as compared to its average volume of 3.84 million shares. North American Palladium Ltd. produces precious metals in Canada. It explores for palladium, platinum, nickel, gold, copper, and other metals.
Has PAL Found The Bottom And Ready To Gain Momentum? Find Out Here
New Gold Inc. (USA) (NYSEMKT:NGD) remained among the day bullish 2.73% and traded with volume of 10.40 million shares in the last session, as compared to average volume of 3.42 million shares. In comparison with 52 week range of $4.68 - $11.14, it faced lowest price of $5.42 during the last trading session whereas its day highest price was $5.83. The company’s total market capitalization is $2.84 billion, along with 503.45 million shares outstanding. New Gold Inc., a gold mining company, engages in the acquisition, exploration, extraction, processing, and reclamation of mineral properties. It primarily explores for gold, silver, and copper deposits.
Will NGD Continue To Move Higher? Find out via this report
Cell Therapeutics Inc (NASDAQ:CTIC) showed 6.89 million shares in volume during the last trading session, while the average trading volume remained 3.60 million shares. The stock kicked off its trading session at $2.99 and closed at $3.05 after rallied 4.45%. Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Why Should Investors Buy CTIC After The Recent Gain? Just Go Here and Find Out
China Pharma Holdings, Inc. (NYSEMKT:CPHI) stock traded during its last trading session with the total traded volume of 4.45 million shares versus its average volume of 84,887.00 shares. The company opened its trade at the price of $0.47 and its closing price was $0.540 after gained 28.52% for the day. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. It offers products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions, and granules.
For How Long CPHI will Fight for Profitability? Read This Trend Analysis report
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)